<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: We evaluated the effect of neutrophil-to-lymphocyte ratio (NLR) on disease-free survival in patients with stages I to III <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: There were 3857 patients identified from our database </plain></SENT>
<SENT sid="2" pm="."><plain>We used receiver operating characteristic (ROC) analysis to identify the best cutoff value of NLR </plain></SENT>
<SENT sid="3" pm="."><plain>A 5-year disease-free survival was used as end point </plain></SENT>
<SENT sid="4" pm="."><plain>Survival analysis was used to assess the NLR effect, after stratification by several clinopathologic factors </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: In the ROC analysis, NLR = 3 had the highest sensitivity and specificity </plain></SENT>
<SENT sid="6" pm="."><plain>Elevated NLR (&gt;3) in <z:hpo ids='HP_0003003'>colon cancer</z:hpo> seemed to accompany larger <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> size (~5 cm) and more advanced T stage </plain></SENT>
<SENT sid="7" pm="."><plain>By multivariate analysis, elevated NLR in <z:hpo ids='HP_0003003'>colon cancer</z:hpo> was associated with an increased risk of disease progression or <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> <z:hpo ids='HP_0011420'>death</z:hpo> [hazard ratio (HR) 1.377, 95  % confidence interval 1.104-1.717, P = 0.014] </plain></SENT>
<SENT sid="8" pm="."><plain>However, elevated NLR in <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e> lost its significance in multivariate analysis (HR 1.121, 95  % confidence interval 0.941-1.336, P = 0.200) </plain></SENT>
<SENT sid="9" pm="."><plain>Patients with elevated NLR had worse outcome, especially for <z:hpo ids='HP_0003003'>colon cancer</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Preoperative NLR influenced the disease-free survival in patients with stages I to III <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>Elevated NLR (&gt;3) was associated with worse outcome (5-year disease-free survival 66.3  % vs. 78.9  % in <z:hpo ids='HP_0003003'>colon cancer</z:hpo>, P &lt; 0.001; 60. 5 % vs. 66.2  % in <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e>, P = 0.008) </plain></SENT>
<SENT sid="12" pm="."><plain>The difference was larger in <z:hpo ids='HP_0003003'>colon cancer</z:hpo> than in <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e> </plain></SENT>
<SENT sid="13" pm="."><plain>NLR should be considered as a prognostic factor for stages I to III <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients after curative surgery </plain></SENT>
</text></document>